Replies to post #141556 on Biotech Values

[DewDiligence]

It’s ironic that PFE didn’t do either the acquisition of Knoll or the Humira co-promotion sought by ABT because PFE was so heavily committed to the success of Bextra, which was subsequently withdrawn from the market.

Good blog by LaMattina. The Timmerman article LaMattina refers to was posted in #msg-74453479.

[DewDiligence]

p.s. I thought the discussion in #msg-75306272 would generate more debate, but you’re the only one to reply so far.